JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of small interfering RNA
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Impact of Cellular Genetic Make-up on Colorectal Cancer Cell Lines Response to Ellagic Acid: Implications of small interfering RNA
Yousef, Amany I; El-Masry, Omar S; Abdel Mohsen, Mohamed A;
  PDF(new window)
 Abstract
Background: activation is an early event in colorectal carcinogenesis and associated mutations have been reported in about 40% of colorectal cancer patients. These mutations have always been responsible for enhancing malignancy and silencing them is associated with attenuation of tumorigenicity. Among downstream effectors are the RAF/MEK/ERK and the PI3K/Akt signaling pathways. PI3K/Akt signaling leads to reduction of apoptosis, stimulated cell growth and enhanced proliferation. Ellagic acid (EA), a naturally occurring antioxidant, has recently emerged as a promising anti-cancer agent. Purpose: To evaluate the impact of cellular genetic makeup of two colon cancer cell lines with different genetic backgrounds, HCT-116 () and Caco-2 (), on response to potential anti-tumour effects of EA. In addition, the influence of silencing in HCT-116 cells was investigated. Materials and Methods: Cellular proliferation, morphology and cell cycle analysis were carried out in addition to Western blotting for detecting total Akt and p-Akt (at Thr308 and Ser473) in the presence and absence of different concentrations of EA. Cell proliferation was also assessed in cells transfected with different concentrations of siRNA or incubated with ellagic acid following transfection. Results: The results of the present study revealed that EA exerts anti-proliferative and dose-dependent pro-apoptotic effects. Cytostatic and cytotoxic effects were also observed. p-Akt (at Thr308 and Ser473) was downregulated. Moreover, EA treatment was found to (i) reduce protein expression; (ii) in cells transfected with siRNA and co-treated with EA, pronounced anti-proliferative effects as well as depletion of p-Akt (at Thr308) were detected. Conclusions: Cellular genetic makeup () was not likely to impose limitations on targeting EA in treatment of colon cancer. EA had a multi-disciplinary pro-apoptotic anti-proliferative approach, having inhibited Akt phosphorylation, induced cell cycle arrest and showed an anti-proliferative potential in HCT-116 cells (expressing mutant ).
 Keywords
Ellagic acid;colorectal cancer;;siRNA;
 Language
English
 Cited by
1.
The anti-oncogenic influence of ellagic acid on colon cancer cells in leptin-enriched microenvironment, Tumor Biology, 2016, 37, 10, 13345  crossref(new windwow)
2.
Natural Polyphenols for Prevention and Treatment of Cancer, Nutrients, 2016, 8, 8, 515  crossref(new windwow)
 References
1.
Aggarwal BB, Takada Y, Oommen OV (2004). From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs, 13, 1327-38. crossref(new window)

2.
Ahmed A Zeeneldin MMS, Ibrahim A Seif El-din , Sara A Frag (2012). Colorectal carcinoma in gharbiah district, Egypt:Comparison between the elderly and non-elderly. J Solid Tumors, 2, 13-23.

3.
Chappell WH, Steelman LS, Long JM, et al (2011). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget, 2, 135-64. crossref(new window)

4.
Danielsen SA, Eide PW, Nesbakken A, et al (2015). Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta, 1855, 104-21.

5.
Diersch S, Wenzel P, Szameitat M, et al (2013). Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget, 4, 277-88. crossref(new window)

6.
Espin JC, Larrosa M, Garcia-Conesa MT, et al (2013). Biological significance of urolithins, the gut microbial ellagic Acidderived metabolites: the evidence so far. Evid Based Complement Alternat Med, 2013, 270418.

7.
Fagone P, Donia M, Mangano K, et al (2013). Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells. Basic Clin Pharmacol Toxicol, 112, 63-9. crossref(new window)

8.
Hyun-Ah Kim R-AL, Byung In Moon, Kuk-Jin Choe (2009). Ellagic acid shows different anti-proliferative effects between the MDA-MB-231 and MCF7 human breast cancer cell lines. J Breast Cancer, 12, 85-91. crossref(new window)

9.
Kao TY, Chung YC, Hou YC, et al (2012). Effects of ellagic acid on chemosensitivity to 5-fluorouracil in colorectal carcinoma cells. Anticancer Res, 32, 4413-8.

10.
Khan MK, Ansari IA, Khan MS (2013). Dietary phytochemicals as potent chemotherapeutic agents against breast cancer:Inhibition of NF-kappaB pathway via molecular interactions in rel homology domain of its precursor protein p105. Pharmacogn Mag, 9, 51-7. crossref(new window)

11.
Knickelbein K, Zhang L (2015). Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis, 2, 4-12. crossref(new window)

12.
Phipps AI, Buchanan DD, Makar KW, et al (2013). KRASmutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer, 108, 1757-64. crossref(new window)

13.
Pratheeshkumar P, Budhraja A, Son YO, et al (2012). Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways. PLoS One, 7, 47516. crossref(new window)

14.
Ramirez de Molina A, Vargas T, Molina S, et al (2015). The ellagic acid derivative 4,4'-di-O-methylellagic acid efficiently inhibits colon cancer cell growth through a mechanism involving WNT16. J Pharmacol Exp Ther, 353, 433-44. crossref(new window)

15.
Sarasqueta AF, Forte G, Corver WE, et al (2013). Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer. BMC Cancer, 13, 277. crossref(new window)

16.
Tahir AA, Sani NF, Murad NA, et al (2015). Combined ginger extract & Gelam honey modulate Ras/ERK and PI3K/AKT pathway genes in colon cancer HT29 cells. Nutr J, 14, 31. crossref(new window)

17.
Teimoori-Toolabi L, Hashemi S, Azadmanesh K, et al (2015). Silencing the wild-type and mutant K-ras increases the resistance to 5-flurouracil in HCT-116 as a colorectal cancer cell line. Anticancer Drugs, 26, 187-96. crossref(new window)

18.
Temraz S, Mukherji D, Shamseddine A (2015). Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Int J Mol Sci, 16, 22976-88. crossref(new window)

19.
Umesalma S, Nagendraprabhu P, Sudhandiran G (2015). Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells. Mol Cell Biochem, 399, 303-13. crossref(new window)

20.
Umesalma S, Sudhandiran G (2011). Ellagic acid prevents rat colon carcinogenesis induced by 1, 2 dimethyl hydrazine through inhibition of AKT-phosphoinositide-3 kinase pathway. Eur J Pharmacol, 660, 249-58. crossref(new window)

21.
Vadlakonda L, Dash A, Pasupuleti M, et al (2013). The Paradox of Akt-mTOR Interactions. Front Oncol, 3, 165.

22.
Vanella L, Di Giacomo C, Acquaviva R, et al (2013). Effects of ellagic Acid on angiogenic factors in prostate cancer cells. Cancers (Basel), 5, 726-38. crossref(new window)

23.
Vinayak S, Carlson RW (2013). mTOR inhibitors in the treatment of breast cancer. Oncology, 27, 38-44.

24.
Yan WF, Wu G, Sun PC, et al (2015). P53 mutations occur more commonly than KRAS mutations in colorectal adenoma. Int J Clin Exp Med, 8, 1370-5.

25.
Zenonos K, Kyprianou K (2013). RAS signaling pathways, mutations and their role in colorectal cancer. World J Gastrointest Oncol, 5, 97-101.

26.
Zhang HM, Zhao L, Li H, et al (2014). Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med, 11, 92-100.